EVALUATION OF ANTICANCER POTENTIAL OF METHANOLIC EXTRACT OF PETALS OF CHRYSANTHEMUM MORIFOLIUM AGAINST HUMAN LIVER CANCER CELL LINE (HEPG2)

Chrysanthemum morifolium is commonly known as chrysanthemum. It has been widely used in traditional medicine due to its various therapeutic effects. Past studies have shown that chrysanthemum extracts possess significant anticancer activity against breast, prostate, and colon cancer cells. The active compounds in chrysanthemum extracts such as flavonoids, sesquiterpenes, and triterpenoids have been found to induce apoptosis (programmed cell death) in cancer cells, inhibit cell proliferation thus prevent cancer cell migration and invasion. Furthermore, chrysanthemum extracts have also been reported to enhance the efficacy of conventional chemotherapy and reduce its side effects. Based on the previous studies the present research has been aimed to determine the anticancer activity of petals of Chrysanthemum morifolium against Hep G2 liver cancer cells by evaluating the cytotoxic potential by MTT assay ((3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) tetrazolium reduction assay), the study of apoptosis mechanism and cell cycle analysis by flow cytometry to understand the cell cycle changes in liver cancer cells when compared with Doxorubicin. The results obtained have demonstrated a prominent anticancer activity of methanolic extract of petals of Chrysanthemum morifolium against liver cancer cell lines at IC₅₀ 44µg/ml.